Cutaneous Leishmaniasis

Lab Diagnosis  Vector Lazarevic (Specialist)

Two studies were done using the two imidazoles derivatives; Itraconazole (Sporanox) and Ketoconazole (Nizoral) for treatment of cutaneous leishmaniasis in Kuwait. According to the results of our studies, together with the results of similar studies in the literature, we are now treating cases of cutaneous leishmaniasis in Kuwait according to the following protocol:

1- Few small lesions are treated with liquid nitrogen.
2- Few large lesions or multiple lesions are treated with either:
       a) Itraconazole oral dose of 200 mg per day for a period of 6-8 weeks.
       b) Ketoconazole oral dose of 600 mg daily for a period of 6 weeks.
3- Resistant lesions not responding to the above treatments are given parentral sodium stibogluconate (Pentostam).

Full-text articles demonstrating our experience in Kuwait with these two drugs: 

1- Cutaneous Leishmaniasis in Kuwait Clinical Experience with Itraconazole.
       (International Journal of Dermatology 1991; Vol. 30, No. 7 (July): 519-521)
2- Ketoconazole in the Treatment of Cutaneous Leishmaniasis in Kuwait.
       (International Journal of Dermatology 1995; Vol. 34, No. 7 (July): 495-497)

Translate page on-line: French, German, Italian, Portuguese, Spanish